Browse > Article
http://dx.doi.org/10.5653/cerm.2012.39.2.46

Fertility preservation in women with cancer  

Lee, Sanghoon (Department of Obstetrics and Gynecology, Korea University College of Medicine)
Song, Jae Yun (Department of Obstetrics and Gynecology, Korea University College of Medicine)
Ku, Seung Yup (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
Kim, Sun Haeng (Department of Obstetrics and Gynecology, Korea University College of Medicine)
Kim, Tak (Department of Obstetrics and Gynecology, Korea University College of Medicine)
Publication Information
Clinical and Experimental Reproductive Medicine / v.39, no.2, 2012 , pp. 46-51 More about this Journal
Abstract
Fertility preservation (FP) is an effort to retain the fertility of cancer patients, and as an emerging discipline, it plays a central role in cancer care. Because of improvement in diagnostic and therapeutic strategies, an increasingly large number of patients are surviving with cancer. FP specialists should make an effort to spread the significance of FP among reproductive women with cancer and provide appropriate education both for associated physicians and for cancer patients who wish to preserve their fertility. Physicians who take part in the initial diagnosis and management of cancer should consider the importance of early referral of young cancer patients to FP specialists and take care of those patients by providing timely information and appropriate counseling. Individualized treatment strategies should be delivered depending on the patient's situation with appropriate team approach.
Keywords
Fertility preservation; Cancer; Referral; Women; Physicians;
Citations & Related Records
연도 인용수 순위
  • Reference
1 American Cancer Society. Breast cancer facts & figures 2005-2006 [Internet]. Atlanta: American Cancer Society Inc.; c2009 [2012 Jun 27]. Available from: http://www.cancer.org/acs/groups/content/@ nho/documents/document/caff2005brfacspdf2005pdf.pdf.
2 Kovacs P, Matyas S, Ungar L. Preservation of fertility in reproductive-age women with the diagnosis of cancer. Eur J Gynaecol Oncol 2008;29:425-34.
3 Rodriguez-Wallberg KA, Oktay K. Options on fertility preservation in female cancer patients. Cancer Treat Rev 2012;38:354-61.
4 Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr 2005:25-7.
5 Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005;62:738-44.
6 Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys 2009;73:1304-12.
7 Green DM, Sklar CA, Boice JD Jr, Mulvihill JJ, Whitton JA, Stovall M, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2374-81.
8 Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab 2006;91:1723-8.
9 Oktem O, Oktay K. Fertility preservation for breast cancer patients. Semin Reprod Med 2009;27:486-92.
10 Azim A, Rauch ER, Ravich M, Witkin S, Oktay K. Ovarian reserve is impaired in cancer patients with normal baseline FSH who previously received chemotherapy as determined by response to controlled ovarian stimulation and anti-mullerian hormone measurements: a controlled study. Fertil Steril 2006;86 (Suppl 2):S123-4.
11 Lee S, Heytens E, Moy F, Ozkavukcu S, Oktay K. Determinants of access to fertility preservation in women with breast cancer. Fertil Steril 2011;95:1932-6.
12 Lee S, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol 2010;28:4683-6.
13 Quinn GP, Vadaparampil ST, Lee JH, Jacobsen PB, Bepler G, Lancaster J, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol 2009;27:5952-7.
14 Suh CO. Radiotherapy for breast cancer. J Korean Med Assoc 2003;46:503-11.
15 Forman EJ, Anders CK, Behera MA. Pilot survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients. J Reprod Med 2009;54:203-7.
16 Armuand GM, Rodriguez-Wallberg KA, Wettergren L, Ahlgren J, Enblad G, Hoglund M, et al. Sex differences in fertility-related information received by young adult cancer survivors. J Clin Oncol 2012;30:2147-53.
17 Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-31.
18 Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
19 Plante M, Gregoire J, Renaud MC, Roy M. The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecol Oncol 2011;121:290-7.
20 Marnitz S, Kohler C, Schneider A, Seiler F, Hinkelbein W. Interindividual variability of lymph drainages in patients with cervical cancer. Implication on irradiation planning. Strahlenther Onkol 2006;182:80-5.
21 Martin JR, Kodaman P, Oktay K, Taylor HS. Ovarian cryopreservation with transposition of a contralateral ovary: a combined approach for fertility preservation in women receiving pelvic radiation. Fertil Steril 2007;87:189.e5-7.
22 Hwang JH, Yoo HJ, Park SH, Lim MC, Seo SS, Kang S, et al. Association between the location of transposed ovary and ovarian function in patients with uterine cervical cancer treated with (postoperative or primary) pelvic radiotherapy. Fertil Steril 2012;97:1387-93.e2.
23 Oktay K, Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Engl J Med 2000;342:1919.
24 Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online 2009;18:769-76.
25 Noyes N, Boldt J, Nagy ZP. Oocyte cryopreservation: is it time to remove its experimental label? J Assist Reprod Genet 2010;27:69-74.
26 Silber SJ. Ovary cryopreservation and transplantation for fertility preservation. Mol Hum Reprod 2012;18:59-67.
27 Donnez J, Silber S, Andersen CY, Demeestere I, Piver P, Meirow D, et al. Children born after autotransplantation of cryopreserved ovarian tissue. a review of 13 live births. Ann Med 2011;43:437-50.
28 Oktay K, Economos K, Kan M, Rucinski J, Veeck L, Rosenwaks Z. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA 2001; 286:1490-3.
29 American Cancer Society. Cancer facts & figures 2009 [Internet]. Atlanta: American Cancer Society Inc.; c2009 [2012 Jun 27]. Available from: http://www.cancer.org/acs/groups/content/@nho/ documents/document/500809webpdf.pdf.
30 Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 2006;11:422-34.
31 Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008;26:2630-5.
32 Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
33 Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-7.
34 Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2006;24:4888-94.
35 Cold S, Düring M, Ewertz M, Knoop A, Møller S. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer 2005;93:627-32.
36 Lee S, Oktay K. Does higher starting dose of FSH stimulation with letrozole improve fertility preservation outcomes in women with breast cancer. Fertil Steril 2010;94 Suppl: S160.
37 Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011;306:269-76.
38 Leonard RC, Adamson D, Anderson R, Ballinger R, Bertelli G, Coeman RE, et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer [abstract]. J Clin Oncol 2010;28 (Suppl 15):89s.
39 Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011;29:2334-41.
40 Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross- King M, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533-8.
41 Partridge AH. Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy? J Clin Oncol 2012;30:479-81.
42 White YA, Woods DC, Takai Y, Ishihara O, Seki H, Tilly JL. Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women. Nat Med 2012;18:413-21.